Saturday 17 October 2026
Export ABSI’s income statement to Excel — free account
Absci Corporation
ABSI Healthcare Biotechnology
Absci Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 38.2% from fiscal 2024. In the quarter to June 2026, revenue fell 46.4%, EPS grew 12.5%, free cash flow fell 71.7% and total debt fell 93.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.25
0.63
−7.09%
Follow ABSI
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Piotroski F-Score |
3 | 3 | 3 | 2 | 4 | — | — | — |
Altman Z-Score |
5.50 | 0.62 | 1.80 | 0.67 | 3.54 | — | — | — |
P/S ratio |
170.48 | 63.70 | 59.39 | 35.72 | 85.20 | 70.08 | 70.08 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(1.90) | (2.52) | (2.42) | 4.14 | 7.43 | 3.61 | (4.11) | — |
P/Operating CF |
(16.36) | (17.03) | (22.76) | (11.06) | (23.85) | (26.29) | (26.29) | — |
Beneish M-Score |
— | — | (3.24) | (2.90) | (2.66) | 0.47 | — | — |
P/B ratio |
2.52 | 1.61 | 1.93 | 0.75 | 1.11 | 0.00 | 0.00 | — |
Price to Tangible BV |
3.23 | 2.15 | 2.65 | 1.02 | 1.41 | 0.00 | 0.00 | — |
EV/Sales |
119.28 | 36.27 | 40.86 | 6.53 | 31.60 | 78.96 | 78.96 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(3.59) | (2.27) | (3.61) | (0.46) | (2.49) | (15.89) | (15.89) | — |
EV/FCF |
(3.60) | (2.29) | (3.58) | (0.39) | (1.53) | (8.13) | (8.13) | — |
Quick Ratio |
6.34 | 4.48 | 3.93 | 5.98 | 7.81 | 7.08 | 3.84 | — |
Current Ratio |
6.57 | 4.67 | 4.08 | 6.17 | 8.07 | 7.25 | 3.94 | — |
Net Debt/EBITDA |
1.32 | 1.30 | 1.32 | 1.79 | 3.74 | 5.10 | 1.59 | — |
Debt/Assets |
0.40% | 1.87% | 3.64% | 3.64% | 1.58% | 8.82% | 20.02% | 0.00% |
Debt/Equity |
0.00 | 0.02 | 0.04 | 0.04 | 0.02 | 0.12 | 0.34 | — |
Asset Turnover |
0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.09 | 0.21 | — |
Operating CF/Net income |
0.81 | 0.70 | 0.58 | 0.78 | 0.59 | 0.22 | 0.25 | — |
Capex/Depreciation |
0.02 | 0.04 | (0.02) | (1.23) | (5.72) | (1.92) | (2.22) | — |
Interest Coverage |
(575.68) | (192.72) | (114.37) | (109.83) | (21.92) | (20.98) | (23.38) | — |
| (62.50%) | (58.04%) | (49.08%) | (32.76%) | (74.63%) | 75.76% | 36.56% | — | |
| (53.59%) | (47.86%) | (41.08%) | (28.08%) | (40.11%) | (91.58%) | (245.19%) | — | |
ROIC |
(163.37%) | (124.30%) | (102.78%) | (62.56%) | (42.83%) | (168.01%) | (162.00%) | — |
Return on Tangible Assets |
(78.00%) | (76.75%) | (83.54%) | (50.12%) | (35.44%) | (68.66%) | (177.09%) | — |
Average Days of Receivables |
0.00 | 0.00 | 139.73 | 98.44 | 108.77 | 121.72 | 39.34 | — |
Research and Development Expense of Revenue |
2,907.79% | 1,408.45% | 840.63% | 1,025.02% | 932.37% | 239.50% | 209.27% | — |
Selling, General and Administrative Expense of Revenue |
1,252.07% | 797.84% | 661.63% | 705.62% | 601.84% | 115.10% | 171.02% | — |
Intangible Assets out of Total Assets |
0.19 | 0.21 | 0.22 | 0.23 | 0.18 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
654.32% | 429.03% | 199.65% | 218.20% | 221.83% | 8.79% | 2.04% | — |
Graham Net Nets |
0.26 | 0.34 | 0.23 | 0.68 | 0.52 | (0.28) | (0.28) | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.97 | 0.00 | — |
Earnings Yield |
(24.36%) | (35.50%) | (32.52%) | (51.33%) | (44.46%) | (16.63%) | (16.63%) | — |
Free Cash Flow Yield |
(19.42%) | (24.88%) | (19.21%) | (47.43%) | (24.21%) | (13.85%) | (13.85%) | — |
Revenue per Share |
0.02 | 0.04 | 0.06 | 0.06 | 0.10 | 0.31 | 0.14 | — |
Operating CF per Share |
(0.68) | (0.66) | (0.70) | (0.90) | (1.22) | (0.71) | (0.40) | — |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.18) | (0.77) | (0.14) | (0.07) | — |
Free Cash Flow per Share |
(0.68) | (0.65) | (0.71) | (1.07) | (1.99) | (0.85) | (0.47) | — |
Cash per Share |
1.05 | 1.16 | 1.24 | 1.98 | 5.30 | 4.51 | 0.86 | — |
Shareholders Equity per Share |
1.39 | 1.62 | 1.91 | 3.02 | 7.37 | 4.32 | 0.76 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
1.39 | 1.62 | 1.91 | 3.02 | 7.37 | 4.32 | 0.76 | — |
Free Cash Flow |
(92.72) | (71.87) | (65.24) | (97.38) | (98.64) | (13.14) | (7.12) | — |
Working Capital |
126.81 | 105.18 | 91.02 | 156.59 | 239.22 | 63.14 | 10.18 | — |
Capital Expenditures |
0.21 | 0.54 | (0.61) | (16.04) | (38.05) | (2.17) | (1.09) | — |
Net Current Asset Value |
122.73 | 99.36 | 79.46 | 140.27 | 212.99 | 51.67 | 5.78 | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
(0.07) | (0.12) | 0.11 | 2.79 | 7.96 | 0.45 | 0.53 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.56 | 0.46 | 0.86 | 0.25 | 0.13 | 0.13 | 0.15 | — |
Cash ROIC |
(27.71%) | (23.07%) | (21.90%) | (20.92%) | (15.51%) | (9.08%) | (24.91%) | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 3.06 | 3.86 | 3.17 | 5.26 | 2.27 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | 1.87 | 1.49 | 1.51 | 0.91 | 0.91 | — |
Average Payables |
14.90 | 5.98 | 1.96 | 5.40 | 5.25 | 1.19 | 1.19 | — |
Average Assets |
214.95 | 215.45 | 269.15 | 373.60 | 257.38 | 54.02 | 9.74 | — |
Average Common Equity |
184.29 | 177.65 | 225.29 | 320.26 | 138.34 | (65.29) | (65.29) | — |
Columns are period end dates